Summary
Boston Scientific Corporation reported strong financial results for the first quarter of 2024, demonstrating robust top-line growth and improved profitability. Net sales increased by 13.8% to $3.856 billion compared to the prior year, driven by broad-based growth across its MedSurg and Cardiovascular segments, with notable strength in Cardiology and Peripheral Interventions. The company also showed significant improvement in net income, which more than doubled year-over-year, highlighting effective operational execution and expanding margins. The company continues to execute on its strategic priorities, including pending acquisitions. The agreement to acquire Axonics, Inc. is progressing through regulatory review, with expected closure in the second half of 2024. Management expressed confidence in its liquidity and ability to fund operations, investments, and potential acquisitions, supported by a strong cash position and an undrawn revolving credit facility. Overall, the quarter's results indicate positive momentum and a solid foundation for future growth.
Financial Highlights
50 data points| Revenue | $3.86B |
| Cost of Revenue | $1.21B |
| Gross Profit | $2.65B |
| SG&A Expenses | $1.36B |
| Operating Expenses | $1.97B |
| Operating Income | $675.00M |
| Interest Expense | $69.00M |
| Net Income | $493.00M |
| EPS (Basic) | $0.34 |
| EPS (Diluted) | $0.33 |
| Shares Outstanding (Basic) | 1.47B |
| Shares Outstanding (Diluted) | 1.48B |
Key Highlights
- 1Net sales grew 13.8% year-over-year to $3.856 billion, exceeding the prior year's $3.389 billion.
- 2Net income attributable to common stockholders significantly increased to $495 million ($0.33 per diluted share) from $300 million ($0.21 per diluted share) in the prior year.
- 3Gross profit margin remained strong at 68.7%, slightly down from 69.3% in Q1 2023, but the company saw increased sales of higher-margin products.
- 4The pending acquisition of Axonics, Inc. is proceeding, with a projected closing in the second half of 2024, subject to regulatory approvals.
- 5Operating expenses increased in line with sales growth, with SG&A up 12% and R&D up 9%, reflecting investments in sales support and product pipeline.
- 6The company maintained a strong liquidity position with $2.329 billion in unrestricted cash and cash equivalents and no amounts outstanding under its $2.750 billion revolving credit facility.
- 7The effective tax rate decreased to 18.9% from 29.4% in the prior year, primarily due to acquisition expenses and discrete tax benefits.